

2023 New Working Committee Studies

Working Committee	Study #	Study Title	Principal Investigators
Acute Leukemia	LK23-01	The impact of allogeneic stem cell transplantation on acute myeloid leukemia and myelodysplastic syndrome with chromosome 3 abnormalities.	Arjun Datt Law
Acute Leukemia	LK23-02	Prognostic impact of cytogenetic and molecular risk classification in AML after hematopoietic stem cell transplant in adolescents and young adults.	Hannah Lust
Cellular Immunotherapy for Cancer	CT23-01	Outcomes of CD19 CAR-T in patients who received lymphodepleting chemotherapy using fludarabine-containing versus other regimens.	Rammurti Kamble/ Nausheen Ahmed/ Siddhartha Ganguly/ Alex Sieg/ Chris Strouse/ Alaa Ali/ Carlos Rodriguez-Bonilla/ Kalyan Nadiminti/ Priyanka Pophali/ Sayeef Mirza/ Lohith Gowda
Cellular Immunotherapy for Cancer	CT23-02	Prolonged cytopenia following anti-B cell maturation antigen chimeric antigen receptor T-cell therapy for multiple myeloma.	Jennifer Logue/Doris Hansen/ Murali Janakiram/ Gurbakhash Kaur
Chronic Leukemia	CK23-01	Identifying the optimal graft-versus-host disease regimen in allogeneic transplantation for myelofibrosis.	Sagar Patel/ Daiei Couriel
Chronic Leukemia	CK23-02	The mutational landscape in myelodysplastic syndrome arising from aplastic anemia and its impact on allogeneic stem cell transplantation outcomes.	Brian Ball/ Ryotaro Nakamura
Donor Health and Safety	DS23-01	Unrelated donor collection efficiency and adverse events during the COVID-19 pandemic	Matthew Seftel
Graft Sources and Manipulation	GS23-01	Impact of donor source in second allogeneic hematopoietic cell transplant in patients with acute leukemia/MDS who relapsed after prior allograft during the current era (2014-2020).	Alexandre Troullioud Lucas/ Andriomachi Scaradavou
Graft Sources and Manipulation	GS23-02	Impact of adherence to cord blood guidelines.	Leland Metheny/ Filippo Milano
GVHD	GV23-01	The effect of calcineurin inhibitor vs post transplant cyclophosphamide (with or without mycophenolate mofetil) based graft-vs-host disease prophylaxis on HLA matched hematopoietic cell transplantation.	Rohtesh Mehta/ Rajneesh Nath

Working Committee	Study #	Study Title	Principal Investigators
GVHD	GV23-02	Incidence of chronic graft versus host disease in cryopreserved versus fresh peripheral blood allogeneic hematopoietic stem cell grafts.	Katie Maurer
Health Services and International Studies	HS23-01	Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation in the United States.	Betty Hamilton/ Sanghee Hong
Immunobiology	IB23-01	Immunoepitome divergence between mismatched HLA and outcome of haploidentical HCT.	Pietro Crivello
Immunobiology	IB23-02	Younger MMUD vs older haploidentical donor HCT.	Rohtesh Mehta
Infection and Immune Reconstitution	IN23-01	Infectious complications in patients with relapsed/refractory multiple myeloma receiving B-cell maturation antigen targeted chimeric antigen receptor T cells.	Kitsada Wudhikarn/ Miguel Angel Perales/ Abu-Sayeeff Mirza/ Lohith Gowda/ Muhammad Bilal Abid/ Srinivas Devarakonda/ Yvonne Efebera
Lymphoma	LY23-01	Efficacy of hematopoietic stem cell transplantation in patients with plasmablastic lymphoma.	Sairah Ahmed
Morbidity, Recovery and Survivorship	MRS23-01	Updated analysis of long-term survival and late deaths after allogeneic hematopoietic cell transplantation for hematologic malignancies and severe aplastic anemia.	Uttam Rao/ Minoo Battiwalla
Non-Malignant Diseases	NM23-01	Impact of conditioning intensity and donor type on outcomes in patients with severe aplastic anemia undergoing upfront or salvage hematopoietic stem cell transplant.	Ahmad Rayes/ Salman Otoukesh/ Ryotaro Nakamura/ Michael Pulsipher
Pediatric Cancer	PC23-01	Post-transplant cyclophosphamide vs. TCR $\alpha\beta$ /CD19+ deplete approaches for haploidentical transplant in pediatric patients with acute leukemias and myelodysplastic syndrome: A CIBMTR/EBMT collaborative study.	Amanda M. Li/ Hemalatha Rangarajan/ Prakash Satwani
Pediatric Cancer	PC23-02	Comparison of bone marrow and peripheral blood stem cells as graft source in children undergoing allogeneic hematopoietic stem cell transplantation for hematological malignancies with unmanipulated haploidentical grafts utilizing post-transplant cyclophosphamide as GvHD prophylaxis.	Anand Srinivasan/ Joerg Krueger
Plasma Cell Disorders	MM23-01	Real world experience of feasibility, safety, efficacy, and outcomes following anti-BCMA CAR T-cell therapy for patients with relapsed or refractory multiple myeloma.	Nausheen Ahmed/ Siddhartha Ganguly/ Binod Dhakal/ Christopher Ferreri/ Krina Patel/ Aimaz Afrough/ Larry Anderson Jr/ Hamza Hashmi/ Saad Usmani/ Surbhi Sidana/ Doris Hansen/ Lohith Gowda/ Sayeeff Mirza/ Ciara Freeman/ Othman Akhtar